Recombinant Anti-cAMP antibody [EP8471] (ab134901)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EP8471] to cAMP
- Suitable for: ELISA, ICC/IF
- Reacts with: Species independent
Related conjugates and formulations
Overview
-
Product name
Anti-cAMP antibody [EP8471]
See all cAMP primary antibodies -
Description
Rabbit monoclonal [EP8471] to cAMP -
Host species
Rabbit -
Specificity
This antibody does not cross react with cGMP, GMP, GDP, cIMP, cCMP, or adenosine. -
Tested applications
Suitable for: ELISA, ICC/IFmore details -
Species reactivity
Reacts with: Species independent -
Immunogen
Chemical/ Small Molecule corresponding to cAMP conjugated to keyhole limpet haemocyanin.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C. -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EP8471 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab134901 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
ELISA |
Use a concentration of 0.25 µg/ml.
|
|
ICC/IF |
Use a concentration of 5 µg/ml.
|
Notes |
---|
ELISA
Use a concentration of 0.25 µg/ml. |
ICC/IF
Use a concentration of 5 µg/ml. |
Target
-
Relevance
Cyclic adenosine monophosphate (cAMP) plays a key role as an intracellular second messenger for transduction events that follow a number of extracellular signals. The G-Protein Coupled Receptors (GPCR) is the largest family of cell surface receptors. They can be activated by different ligands, such as neurotransmitters, hormones, ions, small molecules, peptides, and other physiological signaling molecules. Typically, the binding of the ligands to its receptor resulting in the activation of G-proteins, in return, activates the effector adenylyl cyclase evoking the production of cAMP. The activation of a protein kinase by cAMP results in the phosphorylation of substrate proteins. Currently successful drugs in marketing have been developed to target these receptors. Among the GPCRs, ~367 receptors are potential drug development targets, but only about 20 have been used to generate therapeutically and commercially successful drugs so far. Because the involvement of cAMP can amplify the response of the ligand binding, the second messenger cAMP has been largely employed to monitor the activation of the GPCR to facilitate the therapeutic drug discovery. -
Cellular localization
Secreted -
Alternative names
- 3' 5' cyclic adenosine monophosphate antibody
- Cyclic adenosine monophosphate antibody
- Cyclic AMP antibody
Images
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (2)
ab134901 has been referenced in 2 publications.
- Cheng J et al. Microglial autophagy defect causes parkinson disease-like symptoms by accelerating inflammasome activation in mice. Autophagy 16:2193-2205 (2020). PubMed: 32003282
- Jiang X et al. Pinoresinol promotes MC3T3-E1 cell proliferation and differentiation via the cyclic AMP/protein kinase A signaling pathway. Mol Med Rep 20:2143-2150 (2019). PubMed: 31322181